Bioton to distribute Biomed-Lublin’s Distreptaza drug in Poland

…CEO Maciej Pirog said. Execution of the sales plans set forth in the agreement for 2019 and for the subsequent years will be possible thanks to an ongoing capacity extension that will double Biomed-Lublin’s existing capacity to make Distreptaza from Q3 2018 onwards, Mr Pirog added.

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.